Breaking News

Exposure to Air Pollution During Childhood Associated with Adult Bronchitis

Fred Hutch launches new scientific training program for high school and middle school teachers

Country music star Garth Brooks spends time with patients and celebrates the opening of the New Child Life Zone at UCLA Mattel Children’s Hospital

Pride Day 2024: Celebrating Diversity and Promoting Understanding

Antibody-Drug Conjugate Highly Effective in Preventing Recurrence in Patients with Early Stage HER2+ Breast Cancer, Trial Finds

Celebrating the legacy of Maria Goeppert Mayer

Deep Learning Model Overcomes the Challenge of Real-World Measurements of Isotope Production Target Cooling Systems

US states shape foreign policy amid national China unease, research shows

NIH funds critical center in Detroit to lead efforts to investigate and mitigate health impacts of community-voiced chemical and non-chemical stressors

Is 100% survival after stroke achievable?

28 Jun, 2024

A phase 1 dose expansion study of a first-in-class KAT6 inhibitor (PF-07248144) in patients with advanced or metastatic ER+ HER2− breast cancer.

May 29, 2024 sarah JonasResearch Alert

Post Views: 77

For this presentation at ASCO 2024, please email the media contact for more information.

withyou android app